Pyridinium Crosslinks as Markers of Bone Resorption in Breast Cancer
Author Information
Author(s): C.R. Paterson, S.P. Robins, J.M. Horobin, P.E. Preece, A. Cuschieri
Primary Institution: University of Dundee
Hypothesis
Can urinary excretion of collagen crosslinks indicate bone resorption in breast cancer patients?
Conclusion
The study suggests that measuring urinary collagen crosslinks may help in the early detection of bone metastases in breast cancer patients.
Supporting Evidence
- Eight out of ten patients with metastases had higher crosslink excretion values than the reference interval.
- The mean value for Pyd in patients with metastases was significantly higher than in those without.
- Some patients without known metastases also had raised values of Pyd and Dpd.
Takeaway
Doctors can check urine for special markers to see if breast cancer has spread to bones.
Methodology
Urinary excretion of pyridinoline and deoxypyridinoline was measured in breast cancer patients with and without known bone metastases.
Potential Biases
The assays were performed blind, but the small sample size may introduce bias.
Limitations
The study had a small sample size and further long-term follow-up is needed.
Participant Demographics
20 breast cancer patients, 10 with known bone metastases and 10 without.
Statistical Information
P-Value
p<0.025
Statistical Significance
p<0.025
Want to read the original?
Access the complete publication on the publisher's website